RESEARCH

Efficacy and safety of radiofrequency ablation for calcified benign thyroid nodules: results of over 5 years’ follow-up

Yi Li1,2, Hongying He2, Wen Li1,2, Jiahang Zhao1,2, Naiqiao Ge1,2, Yan Zhang2* and Yukun Luo2*

Abstract
Purpose: To evaluate the efficacy and safety of radiofrequency ablation (RFA) for treating calcified benign thyroid nodules (CBTNs).

Methods: Fifty-two patients with 52 CBTNs who underwent RFA in our hospital were included in this retrospective study. According to the size of calcifications, CBTNs were divided into two groups: the punctate echogenic foci (PEF) group and macrocalcification group. Moreover, the macrocalcification group was further subdivided into two groups, the strong group and the weak group, based on their morphologic characteristics. After the RFA procedure, routine ultrasound (US) and clinical evaluation were performed at 1, 3, 6 and 12 months postoperatively and every 12 months thereafter.

Results: The mean follow-up time was 68.98 ± 7.68 months (60–87 months), and the 5-year mean volume reduction rate (VRR) after RFA was 92.95%, with a complication rate of 0.6% (3/52). The mean initial volume of the macrocalcification group was significantly larger than that of the PEF group (9.94 ± 24.60 ml vs. 0.23 ± 0.22 ml, respectively; P = 0.011). Thus, their VRRs were not comparable between the two groups. However, baseline characteristics did not show statistically significant differences between the strong and weak macrocalcification subgroups. The VRRs of the strong subgroup were significantly lower than those of the weak subgroup at the 3-year, 4-year, and 5-year follow-ups.

Conclusion: RFA was effective and safe for treating CBTNs. Strong macrocalcification was related to the VRR of CBTNs after the RFA procedure.

Keywords: Radiofrequency ablation, Moving shot technique, Benign thyroid nodule, Calcification, Volume reduction rate

Introduction
Calcification frequently occurs in thyroid nodules (TNs), occurring in 19.8–32.1% of TNs [1, 2]. The prevalence of calcification is 8–32% in benign nodules and 26–54% in malignant nodules [3]; the prevalence increases with age and the duration of the presence of nodules [4]. Calcification seems to be more prevalent in malignant nodules than in benign nodules. More specifically, macrocalcifications are more likely to be present in benign nodules than in malignant nodules, while microcalcifications are the opposite. According to ATA, macrocalcifications are a criterion of benignity, whereas microcalcifications in a solid hypoechoic nodule (or in the solid hypoechoic component of a partially cystic nodule) are considered to be at high risk of malignancy (estimated risk of malignancy > 70–90%) [5]. In fact, the number of calcified benign thyroid nodules (CBTNs) is increasing annually due the widespread using of ultrasound (US) and the
aging of the population. Thus, demands for CBTN treatment are increasing in clinical practice.

Surgery is known as the standard treatment for benign TNs. However, it has several drawbacks, such as a high risk of complications, general anaesthesia requirements, permanent scar formation, etc., which could diminish the quality of life [6, 7]. Thus, nonsurgical and minimally invasive thermal ablation, such as radiofrequency ablation (RFA), has emerged as an alternative for patients with TNs who are ineligible or refuse surgery [8, 9]. Technically, RFA uses a high-frequency alternating current (200–1200 kHz) to oscillate between the anode and cathode, agitating tissue ions and generating heat of friction [10]. Depending on the electrode structure, RFA can be divided into monopolar and bipolar RFA. In monopolar RFA, the electrode acts as a cathode, and a grounding pad is required to release the electric current that flows through the patient’s body [11]. In bipolar RFA, the electric current is confined to the tip of the electrode, which contains both the anode and cathode [12]. Therefore, bipolar RFA overcomes the disadvantage of monopolar RFA, which may cause skin burns with the grounding pad at the contact area and can be used in patients with pacemakers or during pregnancy [13, 14]. Korkusuz et al. [10] published a study comparing monopolar RFA and bipolar RFA in the treatment of benign TNs and showed that bipolar RFA was superior to monopolar RFA in terms of technical efficacy (volume reduction), feasibility and patient discomfort.

In addition to RFA, there are other potential local thermal ablative procedures, such as laser ablation (LA), high-intensity focused ultrasound (HIFU), and microwave ablation (MWA). LA is an efficient and precise treatment, but a single fibre can only produce a small ablation volume. Although a larger ablation volume can be achieved by using multiple fibres, it is more difficult to manipulate several fibres simultaneously than a single electrode [15]. Consequently, incomplete ablation of the nodule margin may result. HIFU can generate thermal tissue destruction without any skin penetration. Since the ablation volume formed by each sonication is small, multiple HIFU impulses have to reach the target tissue, which results in a long treatment time [16]. MWA can produce a larger ablation volume and has a lower heat-sink effect than the other thermal ablation procedures. However, microwave energy must be transported in coaxial cables that are thicker in diameter than the wires used for RFA, resulting in a larger diameter of the MWA applicator than the RFA electrode [14, 17]. Therefore, the flexibility of MWA treatment is less than that of RFA in treating marginally located nodule tissue.

At present, RFA is the most widely used and thoroughly evaluated thermal ablation procedure [18]. It has been recommended for patients with pressure symptoms or cosmetic concerns by several guidelines and consensus [19–22]. Nevertheless, few studies have assessed the efficacy and safety of RFA for CBTN, especially the long-term results. Therefore, the purpose of this study is to evaluate the long-term outcomes of RFA for CBTN.

Materials and methods

Patients

The medical records of all benign TNs patients who underwent RFA in our institution between July 2014 and December 2016 were retrospectively reviewed. Nodules that met the following criteria were included: (1) confirmed as benign lesions by US-guided fine needle aspiration (FNA) and/or core-needle biopsy (CNB) before each RFA; (2) detected with hyperechoic foci within the solid component of a nodule; (3) solid nodule composition ≥ 20%; (4) follow-up time ≥ 5 years; (5) refusal or ineligibility for surgery; (6) serum thyroid hormones, TSH (thyroid stimulating hormone) and calcitonin levels within normal range; and (7) age ≥ 18. The exclusion criteria were as follows: (1) benign results in biopsy but shows sonographic evidence, which suspects malignancy, such as extrathyroidal invasion, lymph node metastasis, or distant metastasis; (2) contralateral vocal cord paralysis; (3) history of neck radioiodine therapy; (4) severe coagulation disorder; and (5) serious heart/respiratory/liver/renal failure dysfunction.

The flowchart of patient enrolment is shown in Fig. 1. Of the 459 benign TNs in the 371 patients identified, 104 nodules were detected with calcifications. Among them, 52 nodules were enrolled in this study, according to the inclusion and exclusion criteria mentioned above. These nodules were divided into two groups: the punctate echogenic foci (PEF) group (≤ 1 mm punctate hyperechoic foci with or without posterior acoustic shadowing) and the macrocalcification group (> 1 mm hyperechoic foci with or without posterior acoustic shadowing), according to the size of calcifications. Moreover, the macrocalcification group was subdivided into two groups: a strong group (with posterior acoustic shadowing) and a weak group (without posterior acoustic shadowing), based on their morphologic characteristics (Fig. 2).

Preablation evaluation

Prior to treatment, each nodule underwent routine US and contrast-enhanced ultrasound (CEUS). US was performed with Acuson Sequoiaw 512 (Siemens Healthcare), iU22 (Philips Medical Systems) or M9 (Mindray), and CEUS was performed by injecting 2.4 ml of SonoVue (Bracco International, Italy, Milan) mixed with 5 ml normal saline. Details of nodule size, location, composition, echogenicity, vascularity, and CEUS enhancement degree
Benign thyroid nodules underwent RFA during July 2014 to December 2016 N=459

Without calcifications N=355

Nodules detected with calcifications N=104

Follow-up time < 5 years N=52

Nodules included in the study N=52

PEF group (≤ 1 mm punctate hyperechoic foci) N=22

Macrocalcification group (> 1 mm punctate hyperechoic foci) N=30

Strong group (with posterior acoustic shadowing) N=18

Weak group (without posterior acoustic shadowing) N=12

Fig. 1 The flowchart of patient enrolment

Fig. 2 Types of calcifications: a PEF, b weak macrocalcification, c strong macrocalcification
were recorded. The volume of TNs was approximately calculated by the ellipsoidal formula, which is \( V = \frac{1}{6}abc \) (\( V \) is the volume, \( a \) is the largest diameter, and \( b \) and \( c \) are the other two perpendicular diameters).

Nodule vascularity was scored by colour Doppler US as follows [23]: grade 1, no vascularity; grade 2, peripheral nodular vascularity only; grade 3, mild intranodular vascularity (vascularity < 50%), with or without peripheral nodular vascularity; and grade 4, marked intranodular vascularity (vascularity ≥ 50%), with or without peripheral nodular vascularity.

**RFA procedure using moving-shot technology (MST)**

All RFA procedures were performed by Y.K.L. (who had over 20 years of interventional US experience) using MST. Patients were placed in a conventionally supine position with a fully extended neck. After sterilization and spreading of sterile towels, local anaesthesia was administered by injecting lidocaine (1%) with an 18-gauge PTC needle. If the nodule contained a cystic component, the PTC needle was inserted into the centre of the cystic area to aspirate as much internal fluid as possible, and anhydrous ethanol injection was repeated (Changhai Hospital, Shanghai, China, G510001). The injection amount of anhydrous ethanol was approximately 50% of the aspirate volume. If not, skip this step. Then, a bipolar electrode with a 9-mm active tip (CelonProSurge, Olympus Surgical Technologies, Germany) was inserted into the target nodule, followed by moving-shot ablation with a 3–7 W output power until the transient hyperechoic echotexture completely covered the target area. For large and/or dense calcifications, ablation was first performed at the periphery of the calcification, and then the electrode was advanced into calcifications for further ablation, slowing down the moving rate of the electrode. The tip of the electrode was visualized in real time with US imaging throughout the procedure to minimize possible complications. CEUS was immediately used to assess the ablation zone: if there was no contrast enhancement in the ablation area (indicating the disappearance of microcirculation in the nodules) [24], the ablation was considered complete; if there was any residual enhancement, complementary ablation was performed.

After RFA, patients were observed for 2 h in the hospital to monitor any signs of discomfort and/or complications. Information for each patient was recorded as follows: duration of application, total amount of applied energy, output power, and major and minor complications. The duration of application was defined as the time between the activation of the needle and the end of the activation of the needle. According to tumour ablation standardization of terminology and reporting criteria [25], major complications were events that could result in mortality, disability or seriously affect the patient’s quality of life (i.e., hypothyroidism, hypoparathyroidism, permanent dysphonia, oesophageal injury, tracheal injury, cervical swelling that presses on the trachea and wound infection), and all others were considered minor complications (i.e., self-limiting dysphonia, cervical pain, localized haematoma, localized swelling, and fever).

**Follow-up**

After the RFA procedure, US examinations and clinical evaluations were performed at 1, 3, 6 and 12 months and every 12 months thereafter. Technique efficacy was assessed by the volume reduction rate (VRR), calculated by the following formula: \( \text{VRR} = \left( \frac{\text{initial volume} - \text{final volume}}{\text{initial volume}} \right) \times 100\% \). Nodule regrowth was defined as a ≥ 50% nodule volume increase compared to the minimum recorded volume measured at a given follow-up time point [27–29].

**Statistical analysis**

SPSS statistical analysis software (IBM Version 19.0) was used in this study. Continuous data were expressed as the mean ± SD. The Wilcoxon signed rank-sum test was used to compare the initial nodule volumes between the PEF and macrolcalfication groups, baseline characteristics (initial nodule volume, energy applied per volume, and vascularity) and VRRs (at each follow-up time point) between the strong and weak macrolcalfication subgroups. A t test was used to compare the age between the two macrolcalfication subgroups. Categorical data are expressed as frequencies. Fisher’s exact test was used to compare baseline characteristics (sex and location close to critical structure) between the two macrolcalfication subgroups. A \( p \) value < 0.05 was considered significantly different.

**Results**

**Baseline characteristics**

A total of 52 nodules in 52 patients (39 females, 13 males) were included in this study, and their basic clinical characteristics are presented in Table 1. There were 22 nodules in the PEF group and 30 nodules in the macrolcalfication group (12 nodules were in the weak subgroup, and 18 nodules were in the strong subgroup). The CEUS enhancement degree was as follows: hypoenhancement in 28 nodules, isoenhancement in 11 nodules, hyperenhancement in 2 nodules, mixed enhancement in 9 nodules and unidentified enhancement in 2 nodules (could not be assessed due to the strong acoustic shadowing caused by calcification).
The mean follow-up time was 68.98 ± 7.68 months (60–87 months). The results of each follow-up time point are presented in Table 2 and Fig. 3. It should be noted that not all patients underwent examinations at all the scheduled time points during follow-up. In all the nodules, secondary ablation was performed in 2 nodules (one was in the weak macrocalcification group and the other was in the strong macrocalcification group), and regrowth was observed in 1 nodule (in the strong macrocalcification group) at the 3-year follow-up.

The mean initial volume of the macrocalcification group was significantly larger than that of the PEF group (9.94 ± 24.60 ml vs. 0.23 ± 0.22 ml, respectively; \( P = 0.011 \)). Thus, their VRRs were not comparable. However, the baseline characteristics did not show statistically significant differences between the strong and weak macrocalcification subgroups (all \( p > 0.05 \)), including age, sex, initial volume, energy applied per volume, vascularity and location close to critical structure. The comparative results of macrocalcification subgroups are presented in Table 3 and Fig. 4. The VRRs of the strong subgroup were significantly lower than those of the weak subgroup at the 3-year, 4-year, and 5-year follow-ups (all \( p < 0.05 \)).

Safety
The treatment parameters and complications are presented in Table 4. There were no major complications in all patients, but there were only 3 minor complications.

- **Table 1** Baseline patients’ characteristics before RFA
  
  | Characteristics                  | Data                                      |
  |----------------------------------|-------------------------------------------|
  | Age (years)                      | 45.83 ± 11.12 (18–69)                     |
  | Sex (F/M)                        | 39/13                                     |
  | No. of patients                  | 52                                        |
  | No. of nodules                   | 52                                        |
  | Initial nodule largest diameter(cm) | 1.10 ± 1.18 (0.30–5.80)                   |
  | Initial nodule volume(cm³)       | 5.83 ± 19.17 (0.02–111.59)                |
  | Location                         |                                           |
  | Left lobe                        | 25                                        |
  | Right lobe                       | 25                                        |
  | Isthmic                          | 2                                         |
  | Location close to critical structures (Y/N) | 21/31                                    |
  | Composition                      |                                           |
  | Solid (fluid component ≤ 10%)    | 46                                        |
  | Predominantly solid (fluid component 11–50%) | 4                                      |
  | Predominantly cystic (fluid component 51–80%) | 2                                      |
  | Echogenicity                      |                                           |
  | Hypoechoic                       | 40                                        |
  | Isoechoic                        | 10                                        |
  | Hyperechoic                      | 2                                         |
  | Vascularity                      |                                           |
  | Grade 1                          | 22                                        |
  | Grade 2                          | 6                                         |
  | Grade 3                          | 20                                        |
  | Grade 4                          | 4                                         |
  | CEUS enhancement degree          |                                           |
  | Hypoenhancement                  | 28                                        |
  | Isoenhancement                   | 11                                        |
  | Hyperenhancement                 | 2                                         |
  | Mixed enhancement                | 9                                         |
  | Unidentified enhancement         | 2                                         |
  | Calcification                    |                                           |
  | PEF                              | 22                                        |
  | Macrocalcification               | 30                                        |
  | Weak                             | 12                                        |
  | Strong                           | 18                                        |

Data are expressed as the mean ± SD (range) or frequency (number of nodules)

- **Table 2** The volume and VRR at each follow-up time point after RFA
  
  | Follow-up points   | Volume (ml) | VRR (%) | Nodules |
  |--------------------|-------------|---------|---------|
  | 1 month            | 2.32 ± 8.92 | −265.35 ± 315.35 | 32 |
  | 3 months           | 1.42 ± 5.29 | −41.28 ± 151.11 | 27 |
  | 6 months           | 1.11 ± 3.81 | 49.54 ± 52.51 | 30 |
  | 12 months          | 1.09 ± 3.34 | 73.63 ± 35.55 | 41 |
  | 24 months          | 0.65 ± 2.45 | 84.53 ± 25.98 | 41 |
  | 36 months          | 0.28 ± 0.93 | 90.78 ± 19.82 | 41 |
  | 48 months          | 0.25 ± 0.85 | 91.21 ± 17.43 | 45 |
  | 60 months          | 0.47 ± 1.75 | 92.95 ± 13.71 | 52 |

Data are expressed as the mean ± SD or frequency (number of nodules)

Fig. 3 The VRR changes after RFA at each follow-up time point
One patient suffered from electrode fracture during the RFA procedure, whose initial nodule volume was 6.72 ml. The VRRs during follow-up were as follows: 60.03% at 6 months, 67.66% at 12 months, 98.12% at 24 months and were maintained until 60 months. However, this patient underwent thyroid right lobectomy for anxiety about malignancy conversion at 5 years after RFA.

**Table 3** Comparative results of macrocalcification subgroups

| Variables                        | Strong group (n = 18) | Weak group (n = 12) | P value (2-tailed) |
|----------------------------------|-----------------------|---------------------|-------------------|
| Age (years)                      | 42.67 ± 10.68         | 45.08 ± 12.92       | 0.581             |
| Sex (F/M)                        | 13/5                  | 8/4                 | 1.000             |
| Initial nodule volume (cm³)      | 5.70 ± 14.47          | 16.29 ± 34.61       | 0.459             |
| Energy applied per volume (kJ/ml)| 4.64 ± 5.93           | 3.28 ± 4.11         | 0.472             |
| Vascularity                      | 1.83 ± 0.92           | 2.50 ± 1.17         | 0.099             |
| Location close to critical structure (Y/N) | 6/12                  | 6/6                 | 0.458             |
| VRR (%)                          |                       |                     |                   |
| 1 month                          | −111.46 ± 123.44      | −154.94 ± 136.30    | 0.329             |
| 3 months                         | −64.85 ± 218.10       | 28.68 ± 72.71       | 0.248             |
| 6 months                         | 37.49 ± 155.30        | 57.99 ± 72.06       | 0.194             |
| 12 months                        | 61.15 ± 48.36         | 83.98 ± 17.14       | 0.207             |
| 24 months                        | 74.42 ± 33.79         | 88.26 ± 19.97       | 0.088             |
| 36 months                        | 80.05 ± 28.67         | 94.88 ± 8.79        | 0.036 a           |
| 48 months                        | 81.32 ± 24.52         | 95.44 ± 7.73        | 0.029 a           |
| 60 months                        | 85.03 ± 19.52         | 94.73 ± 8.97        | 0.036 a           |

Data are expressed as the mean ± SD or frequency (number of nodules)

*p values were significantly different

+a Comparison between the weak and strong macrocalcification subgroups

**Discussion**

In our study, the morbidity of calcification in benign nodules was 22.66% (104/459), which is consistent with previous reports [3, 4]. Fifty-two CBTNs in 52 patients were included and observed over 5 years. The 5-year mean VRR after RFA was 92.95%, with a complication rate of 0.6% (3/52). Based on the aforementioned data, RFA was efficient and safe for treating CBTNs.

At present, the classification standard of thyroid nodule calcifications has not achieved consensus. It is generally classified according to its diameter and morphologic characteristics. In terms of diameter, the thresholds of microcalcifications in US include maximum diameters ≤ 2.0 mm, ≤ 1.0 mm and ≤ 0.5 mm [30], of which ≤ 1.0 mm is common. Meanwhile, macrocalcifications are subdivided into various groups by different researchers based on their morphologic features. Kim et al. [31] classified macrocalcifications into annular, crescent, intranodular and calcified spot subtypes. Kobayashi et al. [32] suggested that macrocalcifications could be subclassified as speckled, fragment, massive, or eggshell. Ha et al. [33] proposed that macrocalcifications could be classified as incomplete (thick and peripheral calcifications in less than 50% of the nodule), complete (thick and peripheral calcifications in more than 50% of the nodule) and rim (thickening that measures less than 0.5 mm with a circumference greater than 50%) subtypes. In this study, a maximum diameter ≤ 1.0 mm was taken as the microcalcification threshold, and macrocalcifications were further divided...
into strong and weak subgroups based on the presence or absence of posterior acoustic shadowing.

Microcalcification is generally considered to be a marker of papillary thyroid cancer due to its remarkable association with psammoma bodies (PBs). However, US microcalcification is not equivalent to PBs formation, which could also be present in benign nodules. Researchers have demonstrated that microcalcification does not exclusively represent PBs but also other entities, including stromal calcifications, inspissated colloid, puny fibrosis, microcystic area with acoustic enhancement of posterior wall, etc. [30, 34, 35] To avoid misunderstanding, ACR TIRADS recommended a more precise descriptor, “punctate echogenic foci (PEF)”, to replace “microcalcification” [36]. Accordingly, PEF was adopted in this study. There were 22 nodules with PEF in this study. Punctate hyperechoic foci (≤1 mm) without comet tail artifact were detected in their solid components, which was considered as suspicious US features [5, 20, 23, 36]. They received initial FNA because of the risk of malignancy. FNA is the first-line diagnostic tool for TNs recommended by ATA [5]. It contains two techniques: one is fine needle aspiration cytology (FNAC); the other is fine needle non-aspiration cytology, that is, fine needle capillary sampling (FNCS). FNCS reduces tissue destruction and bloody specimen by obviating aspiration, resulting in better quality smears [37, 38]. While, FNAC is superior to FNCS in acquisition of adequate tissue sample [37, 38]. However, FNA has higher rates of non-diagnostic and inconclusive results (category I and

Table 4  Treatment parameters and complications of RFA

| Characteristics | Data |
|-----------------|------|
| Power (W)       | 3–7  |
| Duration (s)    | 299.58 ± 209.71 (47–1371) |
| Energy (KJ)     | 1.15 ± 1.09 (0.14–6.72) |
| Complication    |      |
| Major           | 0    |
| Minor           |      |
| Self-limiting dysphonia | 0 |
| Cervical pain   | 1    |
| Localized haematoma | 0 |
| Localized swelling | 1 |
| Fever           | 0    |
| Electrode fracture | 1 |

Data are expressed as the mean ± SD (range) or frequency (number of nodules)
III in the Bethesda System for Reporting Thyroid Cytopathology) [23]. CNB demonstrated significantly lower rates of non-diagnostic and inconclusive results (5.5% and 8.0%) than those of FNA (22.6% and 40.2%) [39]. In our institution, CNB is used as a repeated diagnostic tool for patients with non-diagnostic and inconclusive results in initial FNA, which has been recommended by consensus and studies [40–42]. The 22 PEF nodules in this study were all diagnosed as benign by FNA or CNB. However, previous studies reported that the false-negative rate of FNA was 2–18%, and that of CNB was 1–3% [43–47]. Furthermore, false-negative rates for FNA and CNB increased to 13.6–56.6% and 4.2–6.2%, respectively, in nodules with suspicious US features [48, 49]. Therefore, these 22 patients with PEF refused active surveillance and underwent RFA for anxiety about the risk of malignancy.

Macrocalcifications have been shown to be associated with FNA failure, which is attributed to inadequate samples; thus, CNB is recommended for nodules with macrocalcifications [33, 50]. In our study, all macrocalcified nodules underwent CNB and obtained diagnostic results before RFA. Furthermore, macrocalcification is considered a relative contraindication for RFA [19] and may have induced RFA treatment failure in a previous study [51]. Unlike liver tumours, TNs are usually elliptical and exophytic and are unsuitable for fixed ablation technique. In 2006, MST was first reported in thyroid nodule treatment by Kim et al. [52]. It is a key technique for thyroid nodule RFA, which divides nodules into multiple conceptual ablation units and ablates each unit sequentially by moving the electrode tip [53]. MST may generate an ablation area that conforms to the tumour lesion. Over the past decade, experiences with MST for TNs have shown that it could reduce thyroid nodule volume by 50–85%, with a complication rate of approximately 3% [54–56]. However, calcification in a thyroid nodule may restrict electrode tip movement during RFA [57] and reduce the conduction of heat to the target tissue by altering electrical and thermal conductance [53], which result in insufficient ablation and even treatment failure. Macrocalcified nodules may be challenging in RFA for various reasons, such as its difficulty in penetrating dense calcifications and inability to monitor the electrode tip inside acoustic shadowing. In our study, one patient suffered from electrode fracture when attempting to penetrate dense macrocalcifications. Therefore, the ablation of macrocalcified nodules need more precise and meticulous skill while using the electrode needle.

Factors related to the long-term outcomes of ablation are controversial. Sim et al. [58] summarized that it included nodule-related factors (baseline nodule volume and vascularity) and technology factors. Trimboli et al. [59] reported that the only parameter related to the VRR is the energy delivered by RFA. In this study, significant differences were detected in 3-, 4-, and 5-year VRRs between the strong and weak macrocalcification subgroups. Because the baseline characteristics did not show statistically significant differences between these two subgroups, we suggested that strong macrocalcification is associated with VRR. Fukuoka et al. [60] reported that the cumulative rate of upgrade in the calcification pattern, from weak to strong, was 51.8% at 10 years. Therefore, early ablation of macrocalcified TNs, before the upgrade of weak to strong macrocalcification, may yield higher technique efficacy.

The following are limitations of this study. First, it is a retrospective study with a small sample size. Second, the size of calcification was not quantitatively or semi-quantitatively analysed. Third, although data for all patients at the 5-year follow-up time point were completely collected, incomplete follow-up and not performed with a programmed timing may invite important bias. Fourth, all RFA procedures were performed by the same operator, which controlled the influence of operator technique deviation between subgroups comparison. However, it may lead to selection bias and lack of generalizability in other clinical populations. Finally, data were collected from patients who underwent postablation examinations at other hospitals through telephone follow-up, which may introduce bias.

In conclusion, RFA was effective and safe for CBTNs, provided that it is performed by an experienced operator with precise and meticulous skill. Strong macrocalcifications in CBTNs were related to the efficacy of RFA technology. It is necessary to demonstrate whether these findings are reproducible with longer follow-up periods and larger sample size studies.

Acknowledgements
Not applicable.

Author contributions
LY planned and drafted the manuscript; ZY was involved in patient enrolment and data interpretation; HHY, LW, ZJH, and GNQ participated in data collection; LYK performed the RFA procedure and coordinated the study. All authors approved the final manuscript. All authors read and approved the final manuscript.

Funding
The authors have no funding to be reported.
Availibility of data and materials

Based on patient privacy concerns, the datasets related to the present study are not shared openly. They are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

This retrospective study was approved by the Institutional Review Board of People’s Liberation Army General Hospital (Approval number: S2019-211-01). Written informed consent was obtained from each patient prior to RFA. All methods in the present study were performed in accordance with the relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

No competing interests that could compromise the impartiality of the research were reported by the author(s).

Author details

1. Department of Ultrasound, Medical School of Chinese PLA, Beijing, China.
2. Department of Ultrasound, the First Medical Centre, Chinese PLA General Hospital, Beijing, China.

Received: 5 January 2022 Accepted: 30 March 2022

Published online: 22 April 2022

References

1. Lu Z, Mu Y, Zhu H, et al. Clinical value of using ultrasound to assess calcification patterns in thyroid nodules. World J Surg. 2011;35(1):122–7.
2. Chen G, Zhu XQ, Zou X, et al. Retrospective analysis of thyroid nodules by clinical and pathological characteristics, and ultrasonographically detected calcification correlated to thyroid carcinoma in South China. Eur Surg Res. 2009;42(3):137–42.
3. Kooie E, Noguchi S, Yamashita H, et al. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Arch Surg (Chicago, Ill., 1960). 2001;136(3):34–7.
4. Kim BK, Choe YS, Kwon HJ, et al. Relationship between patterns of calcification in thyroid nodules and histopathologic findings. Endocr J. 2013;60(2):155–60.
5. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
6. Trimbolli P, Castellana M, Sconfienza LM, et al. Efficacy of thermal ablation in benign non-functioning solid thyroid node: a systematic review and meta-analysis. Endocrine. 2020;67(2):43–53.
7. Guang Y, He W, Luo Y, et al. Patient satisfaction of radiofrequency ablation for symptomatic benign solid thyroid nodules: our experience for 2-year follow up. BMC Cancer. 2019;19(1):147.
8. Muhammad H, Santhanan P, Russell JO. Radiofrequency ablation and thyroid nodules: updated systematic review. Endocrine. 2021;72(3):619–32.
9. Bernardi S, Palermo A, Grasso RF, et al. Current status and challenges of US-guided radiofrequency ablation of thyroid nodules in the long term: a systematic review. Cancers (Basel). 2021;13(11):2746.
10. Korkusuz Y, Mader A, Groner D, et al. Comparison of mono- and bipolar radiofrequency ablation in benign thyroid disease. World J Surg. 2017;41(10):2530–37.
11. Goldberg SN, Gazelle GS, Mueller PR. Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance. AJR Am J Roentgenol. 2000;174(2):323–31.

12. Yan L, Zhang M, Xie F, et al. Efficacy and safety of radiofrequency ablation for benign thyroid nodules in patients with previous thyroid lobectomy. BMC Med Imaging. 2021;21(1):47.
13. Bernardi S, Lanzilotti V, Papa G, et al. Full-thickness skin burn caused by radiofrequency ablation of a benign thyroid nodule. Thyroid. 2016;26(1):183–4.
14. Dobnig H, Amrein K. Value of monopolar and bipolar radiofrequency ablation for the treatment of benign thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2019;33(4):101283.
15. Ha EJ, Baek JH, Kim KW, et al. Comparative efficacy of radiofrequency and laser ablation for the treatment of benign thyroid nodules: systematic review including traditional pooling and bayesian network meta-analysis. J Clin Endocrinol Metab. 2015;100(5):1903–11.
16. Mainini AR, Monaco C, Pescatorì LC, et al. Image-guided thermal ablation of benign thyroid nodules. J Ultrasound. 2017;20(1):11–22.
17. Feldkamp J, Grunwald F, Luster M, et al. Non-surgical and non-radioiodine techniques for ablation of benign thyroid nodules: consensus statement and recommendation. Exp Clin Endocrinol Diabetes Off J German Soc Endocrinol German Diabetes Assoc. 2020;128(10):687–92.
18. Hegedus L, Frasoldati A, Negro R, et al. European thyroid association survey on use of minimally invasive techniques for thyroid nodules. Eur Thyroid J. 2020;9(4):194–204.
19. Kim JH, Baek JH, Lim HK, et al. Thyroid radiofrequency ablation guideline: Korean society of thyroid radiology. Korean J Radiol. 2018;19(4):632–55.
20. Papini E, Monpeyssen H, Frasoldati A, et al. European Thyroid Association Clinical Practice Guideline for the use of image-guided ablation in benign thyroid nodules. Eur Thyroid J. 2020;9(4):172–85.
21. Ha EJ, Baek JH, Che Y, et al. Radiofrequency ablation of benign thyroid nodules: recommendations from the Asian Conference on Tumor Ablation Task Force. Ultrasonography (Seoul, Korea). 2021;40(1):75–82.
22. Papini E, Pacella CM, Solbiati LA, et al. Minimally-invasive treatments for benign thyroid nodules: a Delphi-based consensus statement from the Italian minimally-invasive treatments of the thyroid (MITT) group. Int J Hyperth. 2019;36(1):376–82.
23. Ha EJ, Chung SR, Na DG, et al. Korean thyroid imaging reporting and data system and imaging-based management of thyroid nodules. Korean Society of thyroid radiology consensus statement and recommendations. Korean J Radiol. 2021;22:2094.
24. Lan Y, Li N, Song Q, et al. Correlation and agreement between superb micro-vascular imaging and contrast-enhanced ultrasound for assessing radiofrequency ablation treatment of thyroid nodules: a preliminary study. BMC Med Imaging. 2021;21(1):75.
25. Ahmed M, Solbiati L, Bracq C, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria—a 10-year update. Radiology. 2014;273(1):241–60.
26. Mauri G, Pacella CM, Papini E, et al. Image-guided thyroid ablation: proposal for standardization of terminology and reporting criteria. Thyroid. 2019;29(5):611–8.
27. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
28. Sim JS, Baek JH. Unresolved clinical issues in thermal ablation of benign thyroid nodules: regrowth at long-term follow-up. Korean J Radiol. 2021;22(8):1436–40.
29. Jiao Z, Luo Y, Song Q, et al. Roles of contrast-enhanced ultrasound in identifying volume change of benign thyroid nodule and optical time of secondary radiofrequency ablation. BMC Med Imaging. 2020;20(1):79.
30. Gao Z, Lu Q, Yan J. Value of differential diagnosis of contrast-enhanced ultrasound in benign and malignant thyroid nodules with microcalcification. Oncol Lett. 2019;17(5):4645–9.
31. Kim BK, Lee EM, Kim JH, et al. Relationship between ultrasonographic and pathologic calcification patterns in papillary thyroid cancer. Medicine (Baltimore). 2018;97(41):e12675.
32. Kobayashi K, Fujimoto T, Ota H, et al. Calcifications in thyroid tumors on ultrasonography: classification types and relationship with histopathological type. Ultrasound Int Open. 2018;4(2):e45-e51.
33. Ha EJ, Baek JH, Lee JH, et al. Core needle biopsy can minimise the non-diagnostic results and need for diagnostic surgery in patients with calcified thyroid nodules. Eur Radiol. 2014;24(6):1403–9.
34. Kobaly K, Kim CS, Langer JE, et al. Macrocalfications do not alter malignancy risk within the American Thyroid Association sonographic pattern system when present in non-high suspicion thyroid nodules. Thyroid. 2021;31(10):1542–8.

35. Tahvildari AM, Pan L, Kong CS, et al. Sonographic-pathologic correlation for punctate echogenic foci in papillary thyroid carcinoma: what are they? J Ultrasound Med Off J Am Inst Ultrasound Med. 2016;35(8):1645–52.

36. Tessler FN, Middleton WD, Grant EG, et al. ACR thyroid imaging, and data system (TI-RADS): white paper of the ACR TI-RADS Committee. J Am Coll Radiol. 2017;14(5):587–95.

37. Archana E, Vijayakumar C, Raj Kumar N, et al. A comparative study of fine-needle aspiration and nonaspiration cytology diagnosis in thyroid lesions. Niger J Surg Off Publ Niger Surg Res Soc. 2020;26(2):147–52.

38. Pinki P, Alok D, Ranjan A, et al. Fine needle aspiration cytology versus fine needle capillary sampling in cytopathological diagnosis of thyroid lesions. Iran J Pathol. 2015;10(1):47–53.

39. Suh CH, Baek JH, Lee JH, et al. The role of core-needle biopsy in the diagnosis of thyroid malignancy in 4580 patients with 4746 thyroid nodules: a systematic review and meta-analysis. Endocrin. 2016;54(2):315–28.

40. Na DG, Baek JH, Jung SL, et al. Core needle biopsy of the thyroid: 2016 consensus statement and recommendations from the Korean Society of Thyroid radiology. Korean J Radiol. 2017;18(1):217–37.

41. Jung SM, Koo HR, Jang KS, et al. Comparison of core-needle biopsy and repeat fine-needle aspiration for thyroid nodules with inconclusive initial cytology. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc (EUFOS). 2021;278(8):3019–25.

42. Joo I, Na DG, Kim JH, et al. Comparison of core needle biopsy and repeat fine-needle aspiration in avoiding diagnostic surgery for thyroid nodules initially diagnosed as atypia/ follicular lesion of undetermined significance. Korean J Radiol. 2022;23(2):280–8.

43. Wang CC, Friedman L, Kennedy GC, et al. A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid. 2011;21(3):243–51.

44. Sung JY, Na DG, Kim KS, et al. Diagnostic accuracy of fine-needle aspiration versus core needle biopsy for the diagnosis of thyroid malignancy in a clinical cohort. Eur Radiol. 2012;22(7):1564–72.

45. Suh CH, Baek JH, Lee JH, et al. The role of core-needle biopsy as a first-line diagnostic tool for initially detected thyroid nodules. Thyroid. 2016;26(3):395–403.

46. Tee YY, Lowe AJ, Brand CA, et al. Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review. Ann Surg. 2007;246(3):714–20.

47. Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of thyroid nodules–2016 update. Endocr Practice Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2016;22(5):622–39.

48. Chung SR, Baek JH, Park HS, et al. Ultrasound-pathology discordant nodules on core-needle biopsy: malignancy risk and management strategy. Thyroid. 2017;27(5):707–13.

49. Chung SR, Baek JH, Choi YJ, et al. The role of core needle biopsy for the evaluation of thyroid nodules with suspicious ultrasound features. Korean J Radiol. 2019;20(1):158–65.

50. Na DG, Kim DS, Kim SJ, et al. Thyroid nodules with isolated macrocalcification: malignancy risk and diagnostic efficacy of fine-needle aspiration and core needle biopsy. Ultrasonography (Seoul, Korea). 2016;35(2):212–9.

51. Park KW, Shin JH, Han BK, et al. Inoperable symptomatic recurrent thyroid cancers: preliminary result of radiofrequency ablation. Ann Surg Oncol. 2011;18(9):2564–8.

52. Kim YS, Rhim H, Tae K, et al. Radiofrequency ablation of benign cold thyroid nodules: initial clinical experience. Thyroid. 2006;16(4):361–7.

53. Baek JH, Lee JH, Valcavi R, et al. Thermal ablation for benign thyroid nodules: radiofrequency and laser. Korean J Radiol. 2011;12(5):525–40.

54. He L, Zhao W, Xia Z, et al. Comparative efficacy of different ultrasound-guided ablation for the treatment of benign thyroid nodules: systematic review and network meta-analysis of randomized controlled trials. PLoS one. 2021;16(1):e0243864.

55. Bernardi S, Giudici F, Cesareo R, et al. Five-year results of radiofrequency and laser ablation of benign thyroid nodules: a multicenter study from the italian minimally invasive treatments of the thyroid group. Thyroid. 2020;30(12):1759–70.

56. Deandrea M, Trimble P, Garino F, et al. Long-term efficacy of a single session of rfa for benign thyroid nodules: a longitudinal 5-year observational study. J Clin Endocrinol Metab. 2019;104(9):3751–6.

57. Yoo RE, Kim JH, Paeng JC, et al. Radiofrequency ablation for treatment of locally recurrent thyroid cancer presenting as a metastatic lymph node with dense macrocalcification: a case report and literature review. Medicine (Baltimore). 2018;97(9):e0003.

58. Sim JS, Baek JH. Long-term outcomes of thermal ablation for benign thyroid nodules: the issue of regrowth. Int J Endocrinol. 2021;2021:9922509.

59. Trimble P, Deandrea M. Treating thyroid nodules by radiofrequency: Is the delivered energy correlated with the volume reduction rate? A pilot study. Endocrine. 2020;69(3):682–7.

60. Fukuoka O, Sugitani I, Ebina A, et al. Natural history of asymptomatic papillary thyroid microcarcinoma: time-dependent changes in calcification and vascularity during active surveillance. World J Surg. 2016;40(3):529–37.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.